Life Sciences

Where IFU errors trigger FDA Class I recalls. Patient safety, not paperwork. Regulatory documentation is the bottleneck on submission timelines and the surface where compliance and patient-safety failures originate.

Document types we work in.

Instructions for Use (IFU) and labeling: Patient-facing and clinician-facing IFUs. Labeling content across global markets with single-source authoring and profiling.
Regulatory submission components: 510(k), PMA, NDA, BLA, ANDA submission content. Module structure and component-level reuse across submissions.
Clinical study documentation: Clinical Study Reports (CSRs), study protocols, investigator brochures.
Validated documentation programs: 21 CFR Part 11-compliant authoring workflows with electronic signatures and audit trails.
Training and procedural content: GxP-aligned training materials, standard operating procedures, manufacturing documentation.

Regulatory frameworks and standards.

21 CFR Part 11: FDA electronic-records and electronic-signatures requirements. Validated authoring workflows that meet Part 11 controls.
GxP / cGMP / cGCP / cGLP: Good Practice frameworks for manufacturing, clinical, and laboratory operations. Documentation as a GxP control artifact.
ISO 13485: Medical device quality-management-system requirements. FDA-recognized standard for device documentation.
MedDRA: Medical Dictionary for Regulatory Activities — controlled terminology for adverse-event reporting and safety documentation.
SNOMED CT: Clinical terminology used in clinical documentation and regulatory submissions.
EU MDR (Medical Device Regulation): Required for any medical device sold into the EU market. Documentation obligations span IFU/labeling, risk-management files, and post-market surveillance — distinct from FDA frameworks and increasingly load-bearing for global device portfolios.
ISO 14971: Risk management for medical devices. The standard FDA recognizes for device risk-management documentation; risk-control traceability runs through it.

AUDIT CYCLE — LIFE SCIENCES

When the documentation gets tested.

Documentation in life sciences gets tested on three different cadences. Submissions are episodic events; surveillance audits are continuous; recall and safety events are unpredictable. The same content estate has to satisfy all three.

Submissions

PMA

ANDA

510(k)

BLA

Surveillance

FDA QSR · ISO 13485 · EU MDR · ICH GCP

Safety events

Form 483 (unpredictable)

Recall trigger (unpredictable)

Representative cadence. Actual schedules vary by product class, regulatory geography, and program.

When this goes wrong.

LIFE SCIENCES / FDA

An IFU error triggers an FDA Class I recall.

Direct remediation runs into the millions. Brand damage lasts years. Class I recalls invoke notification cascades across distribution, customer-facing communications, regulatory reporting, and field-engineer deployment. The document was the safety control — and the safety control failed.

When you’d reach out.

“Our IFU just got flagged in an FDA inspection.”

Tactical, immediate. A 483 observation tied to documentation usually means the IFU content didn't match the labeled use, the labeling didn't match the predicate device, or the IFU wasn't single-sourced and divergent versions surfaced in field copy. The fix runs through architecture before it runs through writing.
“We're approaching an EU MDR submission and the IFUs aren't single-source.”

Pre-submission. EU MDR's documentation requirements multiply if every market variant is independently maintained — translation cost, version control, post-market surveillance reporting all expand linearly with variant count. Single-sourcing under DITA profiling is the structural fix.
“Our GxP-validated authoring environment is brittle and slowing submissions.”

Operational. Validated environments tend to ossify — vendor consolidation, deprecated authoring tools, custom integrations holding the system together. Replacement requires GxP-defensible methodology, not just a new tool.
“A Class III device recall triggered a documentation root-cause review.”

Reactive, post-event. Recalls send investigators looking for the documentation failure. If the content estate isn't auditable — version history, approval chain, traceability to risk controls — the root cause becomes "the entire documentation system" rather than a single document.

Where Extense's capabilities apply.

Information Architecture: Device-family content models with regulatory-variant profiling. Controlled vocabulary aligned to MedDRA. Reuse strategy across IFUs and labeling. Typically Project-Based with a defined acceptance gate against the new content model.
Content Migration: Heavy in this vertical. Legacy Word and FrameMaker IFU estates converted to clean DITA, with QA harnesses that surface pre-existing content errors as part of the migration. Project-Based — fixed scope, fixed fee, conversion-fidelity acceptance criteria.
CCMS & Publishing: CCMS adoption growing fast in regulated content. Validated authoring workflows; multi-format publishing across regulatory submissions and patient-facing surfaces. Project-Based for the implementation; Managed Services for ongoing administration once stable.
AI-Ready Content: Emerges carefully — validation requirements slow but don't stop deployment. RAG over regulated content estates requires evaluation discipline and provenance metadata that survives the pipeline. Often starts as Staff Augmentation during exploratory work; converts to Project-Based once the architecture firms up.

Engagements in this vertical.

A Class III medical device manufacturer consolidating IFUs across global markets.

Single-source DITA across device families, regulatory-variant profiling for FDA-recognized markets, controlled vocabulary aligned to MedDRA. Translation costs reduced through reuse rather than retranslation; submissions accelerated by component-level approval.

A pharmaceutical company restructuring regulatory submission components for FDA eCTD.

Component-level reuse across submission programs; metadata-driven assembly for module structure. Authoring workflows validated under 21 CFR Part 11; audit trails preserved through publication.

Case studies anonymized for client confidentiality. Specific scope and named outcomes available under appropriate NDA channels.

Sample Content Assessment

Submit a 20-page sample (IFU, labeling, or submission component). We'll return a content-readiness assessment — what's recoverable, what's at risk, and what GxP-defensible methodology would change. Two business days, no obligation to proceed.

Submit a sample →